WT1 and acute myeloid leukemia: Furthermore, WT1 overexpression also contributes, as a negative prognostic marker, to the prognosis and therapeutic response of the CN-AML patients in the favorable (NPM1mt/no FLT3ITD) and the unfavorable (FLT3ITD) molecular subgroups (Figure 1 and 2).